Due to limited data on this topic, particularly concerning EDs other than BED, and the uncertain long-term impact of GLP-1 analogs on patients with EDs, comprehensive placebo-controlled studies are needed to evaluate the safety and efficacy of different GLP-1 analogs on diverse EDs across various demographic groups. This evidence concerns the gene GCG and Ehlers-Danlos syndrome.